Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Masaya Suenaga

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111934897. Sources: OpenAlex.

Their work

Papers
19
Trials
0
Grants
0
Labs led
0
Collaborators
65
Papers, trials and grants by year

2014: 3 papers · 2015: none · 2016: 1 paper · 2017: 3 papers · 2018: 6 papers · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 19

  1. FUT2 and FUT3-specific normalization of DUPAN-2 and carbohydrate antigen 19-9 in preoperative therapy for pancreatic cancer: multicentre retrospective study (G… Co-author DOI 10.1093/bjs/znaf049↗
  2. Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08990-w↗
  3. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Co-author DOI 10.1016/j.jmoldx.2020.02.010↗
  4. ASO Author Reflections: Real Prevalence of Occult Cancer Cells in Peritoneal Lavage in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09038-9↗
  5. Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14138↗
  6. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
  7. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. Co-author DOI 10.1038/s41598-018-28253-9↗
  8. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Co-author DOI 10.1073/pnas.1720588115↗
  9. Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001105↗
  10. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms. Co-author DOI 10.1097/mpa.0000000000001110↗
  11. Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification. Co-author DOI 10.1097/mpa.0000000000001186↗
  12. Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6699-8↗
  13. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cance… Co-author DOI 10.1136/gutjnl-2015-311166↗
  14. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2017.72.3502↗
  15. Lack of association between the pancreatitis risk allele CEL-HYB and pancreatic cancer. Co-author DOI 10.18632/oncotarget.15137↗
  16. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. Co-author DOI 10.1002/jso.24147↗
  17. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Co-author DOI 10.1007/s00595-013-0752-9↗
  18. Pancreatoduodenectomy with portal vein resection is feasible and potentially beneficial for elderly patients with pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000136↗
  19. Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. Co-author PMID 25436375↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tsutomu Fujii · 12 shared papers, 2014–2025 · strength 1.05
  2. Yasuhiro Kodera · 13 shared papers, 2014–2025 · strength 0.98
  3. Suguru Yamada · 12 shared papers, 2014–2021 · strength 0.78
  4. Mitsuro Kanda · 10 shared papers, 2014–2021 · strength 0.64
  5. Masamichi Hayashi · 8 shared papers, 2018–2021 · strength 0.61
  6. Fuminori Sonohara · 6 shared papers, 2018–2021 · strength 0.47
  7. Jun Yu · 5 shared papers, 2017–2020 · strength 0.31
  8. Koji Shindo · 5 shared papers, 2017–2020 · strength 0.31
  9. Michael Goggins · 5 shared papers, 2017–2020 · strength 0.31
  10. Ralph H. Hruban · 5 shared papers, 2017–2020 · strength 0.31
  11. Junpei Yamaguchi · 2 shared papers, 2019–2025 · strength 0.27
  12. Christopher Lee Wolfgang · 4 shared papers, 2017–2020 · strength 0.25
  13. Alison P. Klein · 4 shared papers, 2017–2020 · strength 0.25
  14. Tomohisa Otsu · 1 shared paper, 2025 · strength 0.20
  15. Toshio Kokuryo · 1 shared paper, 2025 · strength 0.20
  16. Masaki Sunagawa · 1 shared paper, 2025 · strength 0.20
  17. Haruyoshi Tanaka · 1 shared paper, 2025 · strength 0.20
  18. Nobuhiko Nakagawa · 1 shared paper, 2025 · strength 0.20
  19. Mina Fukasawa · 1 shared paper, 2025 · strength 0.20
  20. Tomoki Ebata · 1 shared paper, 2025 · strength 0.20
  21. Norifumi Hattori · 3 shared papers, 2018 · strength 0.20
  22. Marcia Irene Canto · 3 shared papers, 2017–2020 · strength 0.19
  23. Jin Peng He · 3 shared papers, 2017–2020 · strength 0.19
  24. Anne M. Macgregor-Das · 3 shared papers, 2017–2020 · strength 0.19
  25. Hiroyuki Sugimoto · 4 shared papers, 2014–2016 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.